The Commonwealth Neuroendocrine Tumour Group (CommNETs) held its first Clinical Trials Development Workshop in Hong Kong on 8-9 December, followed by an Executive Committee Strategy Day on 10 December.
In early 2018, CommNETs put a new Executive Committee in place. The Committee includes four AGITG members: Prof Eva Segelov (also Co-Convenor), Prof Tim Price, Dr Sharon Pattison and Dr David Wyld. It also includes four members from the Canadian Cancer Trials Group.
Eight clinical trial concepts were selected for presentation at the workshop:
- TEMPTATION: Temozolomide and PD-1 to Activate the Immunogenicity of NETs
Dr Ben Lawrence
- ISABR: A Phase II study of Immunotherapy In Addition to Stereotactic Ablative Radiation Therapy in Unresectable/metastatic, progressive Grade 2-3 Neuroendocrine Neoplams
Dr Sten Myrehaug, Dr David Chan
- FOLFIRI versus Tremelimumab + Durvalumab for Progressive GEP-NEC: Immuno-Oncology in NEC (IONEC Trial)
Dr Michael Vickers
- Phase II trial of doxorubicin/lurbinectedin in high-grade neuroendocrine carcinoma of the digestive system
A/Prof Thierry Alcindor
- A randomised trial of continuing versus ceasing somatostatin analogues following completion of Peptide receptor radionuclide therapy (PRRT) with lutetium 177
Dr Matthew Burge
- Continuation of somatostatin analoguess (SSAs) beyond progression after starting targeted therapy in advanced, well-differentiated non-functional pancreatic neuroendocrine tumours (pNETs)
Dr Rachel Goodwin
- BLOCKNET: Addition of Beta Blocker therapy to SSA for advanced, well-differentiated functional and non-functional neuroendocrine tumours of any origin
Prof Eva Segelov
Robust discussion followed each presentation and then a vote determined four concepts to be further developed at the workshop and in the coming months.